Funding News Edition: September 07, 2022 See more articles in this edition
Small businesses are invited to submit research proposals in response to A Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals published on August 8, 2022. The solicitation serves as a vehicle for offerors to propose research projects on a multitude of scientific topics from across NIH.
Proposals are due by November 4, 2022, at 5 p.m. Eastern Time.
If you missed the August 24 webinar about the contract solicitation, check for a video recording and webinar slides under the Past Events tab on NIH SEED’s Events webpage.
Note: This SBIR contract solicitation is distinct from the 2022 SBIR and STTR Omnibus/Parent Grant Solicitations for the NIH, CDC, and FDA released in June, which are funding opportunity announcements for grant awards (despite the word “solicitation” appearing in the titles). Learn about those grant opportunities in our July 7, 2022 article “NIH Small Business Opportunities and Priority Topics for 2022.”
The table below summarizes each of NIAID’s research topics of interest for contract proposals. Refer to the attachment posted within the solicitation linked above for full details, including the number of anticipated awards and descriptions of required activities and deliverables.
| Topic Number and Title | Project Goal | Proposal Types | Budget (Total Costs) |
|---|---|---|---|
| 113. Development of a Simian Immunodeficiency Virus (SIV) and Simian Human Immunodeficiency Virus (SHIV) Database | To develop and maintain a database that represents information about SIV and SHIV strains and their biological properties, and a user-friendly web-based interface that enables data search and retrieval using graphic displays. | Fast Track |
Phase I: $300,000 for up to 1 year Phase II: $2 million for up to 3 years |
| 114. Point-of-Care HIV Viral Load, Drug Resistance, and Adherence Assays | To propose novel, low-cost, real-time point-of-care assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring; ultimately, increase viral suppression under combination antiretroviral therapy and effectiveness of pre-exposure prophylaxis. |
Fast Track, Phase I |
Phase I: $300,000 for up to 1 year Phase II: $2 million for up to 3 years |
| 115. Development of Diagnostics to Differentiate HIV Infection from Vaccine-Induced Seropositivity | To develop new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to vaccine-induced sero-positivity, with high sensitivity and specificity. |
Fast Track, Phase I |
Phase I: $300,000 for up to 1 year Phase II: $2 million for up to 3 years |
| 116. Adjuvant Discovery for Vaccines for Infectious and Immune-Mediated Diseases | To support the screening for new adjuvant candidates for vaccines against infectious diseases, autoimmune and allergic diseases, or transplantation tolerance; their characterization; and early-stage optimization. |
Fast Track, Phase I Direct-to-Phase II |
Phase I: $300,000 each year for up to 2 years Phase II: $1 million each year—with appropriate justification—for up to 3 years |
| 117. Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases | To support the preclinical development and optimization of a single lead adjuvant for use in vaccines to prevent or treat human disease caused by infectious pathogens or to treat immune-mediated diseases. | Fast Track, Phase I, Direct-to-Phase II |
Phase I: $300,000 each year for up to 2 years Phase II: $1 million each year—with appropriate justification—for up to 3 years |
| 118. Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models | To develop, validate, and produce adjuvants that are based on, or similar to, compounds or formulations previously successfully used in clinical trials, for use by the broader research community, either as commercial products or through licensing agreements. | Fast Track, Phase I, Direct-to-Phase II |
Phase I: $300,000 each year for up to 2 years Phase II: $1.5 million—with appropriate justification—for up to 3 years |
| 119. Adaptation of CRISPR-based in vitro Diagnostics for Rapid Detection of Select Eukaryotic Pathogens | To adapt CRISPR-based diagnostic technologies to detect select eukaryotic pathogens at the point of need with higher sensitivity and specificity than current rapid diagnostic tests, including simplified sample-preparation protocols, robust target enrichment protocols, and a field-amenable readout. | Fast Track, Phase I |
Phase I: $300,000 for up to 1 year Phase II: $1.5 million for up to 3 years |
| 120. Modular Sample Preparation for In-Field Viral Discovery | To develop modular, rapid, and reliable sample processing technologies that can be used in combination with an established diagnostic platform for the detection of viral pathogens with pandemic potential. | Fast Track, Phase I |
Phase I: $300,000 for up to 1 year Phase II: $1.5 million for up to 3 years |
| 121. Artificial Intelligence to Improve Clinical Microscopy for Diagnosis of Infectious Diseases | To develop artificial intelligence applications to improve clinical microscopy for diagnosis of infections, especially automated smear reading of blood, sputum, stool, or other clinical samples with the goal of improving current, widely used diagnostic tools. | Fast Track, Phase I |
Phase I: $300,000 for up to 1 year Phase II: $1.5 million for up to 3 years |
| 122. Advanced and Immersive Visualization Tools for Infectious and Immune-Mediated Disease Research | To support, develop, or adapt innovative, robust, user-focused tools for data visualization and analysis that are applicable to basic and clinical infectious and immune-mediated diseases. Tools should integrate new and emerging 3D technologies in visualization, analysis, and communication of research data. | Fast Track, Phase I, Direct-to-Phase II |
Phase I: $300,000 for up to 1 year Phase II: $1.5 million for up to 3 years for Direct-to-Phase II |
| 123. Data Science Tools for Infectious and Immune-Mediated Disease Research | To support the new development of innovative, robust informatics/data science tools, or enhancement or adaptation of existing tools for use in infectious, immune, and allergic diseases; should improve data management, data integration or analysis, or FAIR-ness of data. | Fast Track, Phase I, Direct-to-Phase II |
Phase I: $300,000 for up to 1 year Phase II: $1.5 million for up to 3 years for Direct-to-Phase II |
Your contract proposal should address only one topic; if you wish to pursue multiple topics, submit a separate offer for each topic. Submit your proposal(s) through the electronic Contract Proposal Submission. Direct any technical questions about the solicitation and NIAID’s topics to Charles Jackson in NIAID’s Office of Acquisitions at charles.jackson@nih.gov.
Find general information and advice on our Small Business Programs page and contact Natalia Kruchinin at kruchininn@mail.nih.gov for funding questions specific to small businesses.